Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Summary

This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Timeline

Start

2018-05-04

Primary completion

2020-04-15

Completion

2020-04-15

Publications

• Oosthoek M, In 't Veld SGJG, Vermunt L, Ye Y, van Ingen M, Koel-Simmelink M, Vijverberg EGB, Saxena S, Hersch S, Irizarry M, Sachdev P, Teunissen CE. Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Abeta+ and Abeta- dementia with Lewy bodies patients. Alzheimers Res Ther. 2026 Apr 24;18(1):139. doi: 10.1186/s13195-026-02065-w.

Drugs

Indications